Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05923359 · ClinicalTrials.gov registry record · NA

Realtime Diagnosis From Electrocardiogram Artificial Intelligence-Guided Screening for Atrial Fibrillation With Long Follow-Up (REGAL)

A NA study of Atrial Fibrillation, sponsored by Mayo Clinic.

Active
Registry status
NA
Development phase
2,000
Enrollment target
1
Study location

NCT05923359: Active NA study of Atrial Fibrillation, sponsored by Mayo Clinic.

NCT05923359 is a NA study of Atrial Fibrillation that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 2,000 participants, below the 2,987-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05923359, a NA study of Atrial Fibrillation, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
2,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to test whether Apple Watch, used as a long-term monitoring device, can enable early detection of atrial fibrillation.

Primary Outcome

Number of participants diagnosed with atrial fibrillation

Conditions Studied

Interventions

  • OTHER Apple Watch

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2024-04-10
Est. Completion 2026-09
Phase NA
Mayo Clinic

2,844 total trials

What the registry record for NCT05923359 still lists

NCT05923359 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,987-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (33% lower).

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Apple Watch is the first listed.

NCT05923359 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05923359 about?

NCT05923359 is a clinical study titled "Realtime Diagnosis From Electrocardiogram Artificial Intelligence-Guided Screening for Atrial Fibrillation With Long Follow-Up (REGAL)". The purpose of this research is to test whether Apple Watch, used as a long-term monitoring device, can enable early detection of atrial fibrillation.

What is the current status of trial NCT05923359?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 2,000 participants. The study started on 2024-04-10. Estimated completion is 2026-09.

What conditions does trial NCT05923359 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT05923359?

The interventions under investigation include: Apple Watch (OTHER).

Who is sponsoring clinical trial NCT05923359?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05923359 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05923359's enrollment target sits among peer trials

2,000 27th of 202 higher than 176 of 202 other Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05923359, the US trial registry maintained by the National Library of Medicine. NCT05923359 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.